Furthermore, CDK12 deficiency has been found to exhibit synthetic lethality when its paralog CDK13 is pharmacologically targeted, suggesting that this could be a promising novel treatment approach for this type of prostate cancer [49,50]. This evidence concerns the gene CDK13 and prostate carcinoma.